Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).

被引：0

作者：

Cheng, Ann-Lii

Cornelio, Gerardo H.

Shen, Lin

Price, Timothy Jay

Yang, Tsai-Shen

Chung, Ik-Joo

Dai, Guanghai

Lin, Jen-Kou

Sharma, Atul

Yeh, Kun-Huei

Ma, Brigette

Zaatar, Adel

Guan, Zhongzhen

Masood, Nehal

Srimuninnimit, Vichien

Yau, Thomas Cheung

Sarholz, Barbara

Lim, Robert S. C.

机构：

[1] Natl Taiwan Univ Hosp, Taipei, Taiwan

[2] San Juan De Dios Hosp, Pasay City, Philippines

[3] Peking Univ, Canc Hosp, Minist Educ, Dept Gastrointestinal Oncol,Key Lab Carcinogenesi, Beijing 100871, Peoples R China

[4] Queen Elizabeth Hosp, Adelaide, SA, Australia

[5] Chang Gung Mem Hosp, Taoyuan, Taiwan

[6] Chonnam Natl Univ, Hawsun Hosp, Hwasuneup, South Korea

[7] Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China

[8] Taipei Vet Gen Hosp, Taipei, Taiwan

[9] All India Inst Med Sci, New Delhi, India

[10] Chinese Univ Hong Kong, Prince Wales Hosp, Sha Tin, Hong Kong, Peoples R China

[11] Mt Miriam Canc Hosp, George Town, Malaysia

[12] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China

[13] Aga Khan Univ & Hosp, Karachi, Pakistan

[14] Siriraj Hosp, Bangkok, Thailand

[15] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China

[16] Merck KGaA, Darmstadt, Germany

[17] Natl Univ Hlth Syst, Singapore, Singapore

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e14501

引用

页数：1

共 50 条

[1] Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Cheng, Ann-Lii
Cornelio, Gerardo
Shen, Lin
Price, Timothy
Yang, Tsai-Sheng
Chung, Ik Joo
Dai, Guang-Hai
Lin, Jen-Kou
Sharma, Atul
Yeh, Kun-Huei
Ma, Brigette
Zaatar, Adel
Guan, Zhongzhen
Masood, Nehal
Srimuninnimit, Vichien
Yau, Thomas
Gibbs, Peter
Wang, Xiuwen
Doval, Dinesh Chandra
Oh, Seung-Taek
Shim, Byoung Yong
Gorospe, Charity
Wang, Hwei-Ming
Sirachainan, Ekaphop
Hill, Andrew
Suh, Kwang Wook
Beier, Frank
Chatterjee, Sudipto
Lim, Robert
CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E73 - E88
[2] Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab plus first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
Price, Timothy Jay
Shen, Lin
Ma, Brigette
Esser, Regina
Chen, Wen-Feng
Gibbs, Peter
Lim, Robert S. C.
Cheng, Ann-Lii
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Multicenter phase II study of FOLFOX or biweekly XELOX and cetuximab as first-line treatment in patients with wild-type KRAS/BRAF metastatic colorectal cancer (mCRC) (FLEET study)
Kim, Ho Min
Soda, Hitoshi
Hazama, Shoichi
Takahashi, Takao
Nagata, Naoki
Kotaka, Masahito
Kono, Emiko
Terada, Itsurou
Fukunaga, Mutsumi
Oba, Koji
Hasegawa, Junichi
Sakamoto, Junichi
Mishima, Hideyuki
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[4] FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC)
Brodowicz, Thomas
Vrbanec, Damir
Kaczirek, Klaus
Ciuleanu, Tudor-Eliade
Knittelfelder, Regina
Lindner, Elisabeth
Messinger, Diethelm
Zielinski, Christoph
Streubel, Berthold
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[5] Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).
Cheng, Ann-Lii
Cornelio, Gerardo H.
Shen, Lin
Price, Timothy Jay
Yang, Tsai-Sheng
Chung, Ilk Joo
Dai, Guanghai
Lin, Jen-Kou
Sharma, Atul
Yeh, Kun-Huei
Ma, Brigette
Zaatar, Adel
Guan, Zhongzhen
Masood, Nehal
Srimuninnimit, Vichien
Yau, Thomas Cheung
Beler, Frank
Chatterjee, Suipto
Lim, Robert S. C.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[6] Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer
Price, Timothy
Shen, Lin
Ma, Brigette
Esser, Regina
Chen, Wenfeng
Gibbs, Peter
Lim, Robert
Cheng, Ann-Lii
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (04) : 225 - 230
[7] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
Hitoshi Soda
Hiromichi Maeda
Junichi Hasegawa
Takao Takahashi
Shoichi Hazama
Mutsumi Fukunaga
Emiko Kono
Masahito Kotaka
Junichi Sakamoto
Naoki Nagata
Koji Oba
Hideyuki Mishima
BMC Cancer, 15
[8] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
Soda, Hitoshi
Maeda, Hiromichi
Hasegawa, Junichi
Takahashi, Takao
Hazama, Shoichi
Fukunaga, Mutsumi
Kono, Emiko
Kotaka, Masahito
Sakamoto, Junichi
Nagata, Naoki
Oba, Koji
Mishima, Hideyuki
BMC CANCER, 2015, 15
[9] A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2)
Iwamoto, S.
Hazama, S.
Kin, H.
Takemoto, H.
Kobayashi, K.
Takahashi, Y.
Kobayashi, M.
Maeda, H.
Nagata, N.
Oba, K.
Sakamoto, J.
Mishima, H.
ANNALS OF ONCOLOGY, 2016, 27 : 46 - 46
[10] FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study
Personeni, Nicola
Rimassa, Lorenza
Verusio, Claudio
Barni, Sandro
Rubino, Luca
Bozzarelli, Silvia
Villa, Eugenio
Carnaghi, Carlo
Tronconi, Maria Chiara
Gerardi, Chiara
Galli, Francesca
Floriani, Irene
Destro, Annarita
Raschioni, Carlotta
Labianca, Roberto
Santoro, Armando
CLINICAL COLORECTAL CANCER, 2015, 14 (03) : 162 - 169

← 1 2 3 4 5 →